TLF

Target Lesion Failure

The efficacy profile of EluNIR remains strong for a duration of 1 to 2 years when compared to other top-performing drug-eluting stents. EluNIR presents outstanding clinical results with a low TLF of 7.0% at 2 years1.

EluNIR TLF

*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article

EluNIR MI

*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article

MI

Myocardial Infarction

EluNIR shows similar rates of MI compared to other top drug-eluting stents, with an incidence of 5.0% within a two-year period1.

ST

Stent Thrombosis Definite/
Probable

The EluNIR was found non-inferior to Resolute Integrity in a broad, less selected ‘more comers’ population with 0.04mm in-stent late-loss at 6 months with 3.4% target lesion failure at 12 months2.

EluNIR ST

*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article

EluNIR Stent Loss

*January 2020 | Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Read Article

In Stent

Late Loss

Cumulative Distribution Function

EluNIR was found non-inferior to Resolute Integrity in a broad, less selected ‘more comers’ population with 0.04mm in-stent late-loss at 6 months.